NASDAQ:PRPO

Precipio - PRPO Stock Forecast, Price & News

$0.88

-0.02 (-2.16%)

(As of 01/26/2023 04:14 PM ET)

Add

Compare

Today's Range: $0.88
▼
$0.94
50-Day Range: $0.50
▼
$0.91
52-Week Range: $0.47
▼
$1.77

Volume: 47,383 shs
Average Volume: 141,975 shs
Market Capitalization: $20.20 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

Precipio MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.34% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.97
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$25,950 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.45 out of 5 stars

Medical Sector

972nd out of 1,048 stocks

Analytical Instruments Industry

28th out of 28 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Precipio.

3.0

Short Interest

Percentage of Shares Shorted
0.34% of the outstanding shares of Precipio have been sold short.
Short Interest Ratio / Days to Cover
Precipio has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Precipio has recently increased by 7.37%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Precipio does not currently pay a dividend.
Dividend Growth
Precipio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PRPO.

2.8

News and Social Media Coverage

News Sentiment
Precipio has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Precipio this week, compared to 1 article on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Precipio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $25,950.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 8.50% of the stock of Precipio is held by insiders.
Percentage Held by Institutions
Only 9.62% of the stock of Precipio is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Precipio is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Precipio is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Precipio has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Precipio (NASDAQ:PRPO) Stock

Precipio, Inc.is a cancer diagnostics and reagent technology company, which provides diagnostic products and services to the oncology market. Its products include ICP, HemeScreen, and IV-Cell, and services include primary diagnostic, SmartPath, SmartGen, HemeScreen Panel, and ICE COLD-PCR. The company was founded on March 6, 1997 and is headquartered in New Haven, CT.

Receive PRPO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precipio and its competitors with MarketBeat's FREE daily newsletter.

PRPO Stock News Headlines

January 26, 2023 | americanbankingnews.com

Richard A. Sandberg Buys 20,000 Shares of Precipio, Inc. (NASDAQ:PRPO) Stock

January 11, 2023 | finance.yahoo.com

Precipio Signs Another Major HemeScreen™ Customer

January 26, 2023 | PressReach (Ad)

Stocks News Announcement

Don't miss this update. Read the press release about Small Pharma.

December 6, 2022 | finance.yahoo.com

Precipio Signs Additional Major HemeScreen™ Customer

November 7, 2022 | finance.yahoo.com

Precipio Presents Poster on HemeScreen® Study at Association of Molecular Pathology (AMP) 2022 Annual Conference

November 2, 2022 | finance.yahoo.com

Precipio Announces Third Quarter Shareholder Update Call

October 18, 2022 | finance.yahoo.com

RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency - Yahoo Finance

October 18, 2022 | finance.yahoo.com

Precipio, Inc. (NASDAQ:PRPO) Is Expected To Breakeven In The Near Future

January 26, 2023 | PressReach (Ad)

Stocks News Announcement

Don't miss this update. Read the press release about Small Pharma.

October 7, 2022 | finance.yahoo.com

Medical Device and Diagnostic Reimbursements Expert Joins NDA Partners as Expert Consultant - Yahoo Finance

October 7, 2022 | benzinga.com

Precipio And 2 Other Penny Stocks Insiders Are Aggressively Buying - Liberty Star Uranium (OTC:LBSR), Cle - Benzinga

September 17, 2022 | finance.yahoo.com

Point of Care (PoC) Infectious Disease Testing Market Surging Over 4X Touching USD 4.22 Billion by 2028 | BlueWeave Consulting - Yahoo Finance

September 17, 2022 | globenewswire.com

Point of Care (PoC) Infectious Disease Testing Market Surging Over 4X Touching USD 4.22 Billion by 2028 | BlueWeave Consulting - GlobeNewswire

September 15, 2022 | globenewswire.com

Precipio Signs Agreement with Another Major US Healthcare Distributor for HemeScreen - GlobeNewswire

September 15, 2022 | finance.yahoo.com

Precipio Signs Agreement with Another Major US Healthcare Distributor for HemeScreen™

September 1, 2022 | reuters.com

PRPO.OQ - Precipio Inc | Stock Price & Latest News | Reuters

August 25, 2022 | globenewswire.com

Sharon Robins Joins Precipio's Products Division as Senior - GlobeNewswire

August 24, 2022 | finance.yahoo.com

Sharon Robins Joins Precipio’s Products Division as Senior Director of Laboratory & Hospital Sales

August 16, 2022 | seekingalpha.com

Precipio, Inc. (PRPO) CEO Ilan Danieli on Q2 2022 Results - Earnings Call Transcript - Seeking Alpha

August 16, 2022 | globenewswire.com

Precipio Launches New 1-Step Technology for all HemeScreen Assays - GlobeNewswire

August 16, 2022 | finance.yahoo.com

Precipio Launches New 1-Step Technology for all HemeScreen Assays

August 10, 2022 | globenewswire.com

Toni-Ann Mills Joins Precipio's Products Division to Lead - GlobeNewswire

August 10, 2022 | finance.yahoo.com

Toni-Ann Mills Joins Precipio’s Products Division to Lead Channel Partner Training, Learning & Development

August 8, 2022 | benzinga.com

Precipio Announces Second Quarter Shareholder Update Call - Benzinga

August 8, 2022 | finance.yahoo.com

Precipio Announces Second Quarter Shareholder Update Call

August 7, 2022 | reuters.com

PRPO.O - Precipio Inc | Stock Price & Latest News | Reuters

July 21, 2022 | seekingalpha.com

Precipio to distribute HemeScreen through Fisher Healthcare channel - Seeking Alpha

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PRPO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precipio and its competitors with MarketBeat's FREE daily newsletter.

PRPO Company Calendar

Last Earnings: 11/10/2022
Today: 1/26/2023
Next Earnings (Estimated): 3/29/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Analytical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PRPO
CUSIP: N/A
CIK: 1043961
Web: www.precipiodx.com
Phone: (203) 787-7888
Fax: 402-452-5401
Employees: 54
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.52)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,530,000.00
Net Margins: -128.09%
Pretax Margin: -127.93%
Return on Equity: -56.55%
Return on Assets: -44.89%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 1.68
Quick Ratio: 1.53

Sales & Book Value

Annual Sales: $8.85 million
Price / Sales: 2.28
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.08 per share
Price / Book: 0.82

Miscellaneous

Outstanding Shares: 22,820,000
Free Float: 20,880,000
Market Cap: $20.20 million
Optionable: Not Optionable
Beta: 2.16

Key Executives

Ilan Danieli
Chief Executive Officer & Director

Ahmed Zaki Sabet
Chief Operating Officer

Matthew Gage
CFO, Director-Financial Report & Analysis

Ayman A. Mohamed
Vice President-Research & Development

Ori Karev
Chief Strategy Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions

PRPO Stock - Frequently Asked Questions

How have PRPO shares performed in 2023?: Precipio's stock was trading at $0.5514 at the start of the year. Since then, PRPO shares have increased by 61.4% and is now trading at $0.89.
View the best growth stocks for 2023 here.
When is Precipio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our PRPO earnings forecast.
How were Precipio's earnings last quarter?: Precipio, Inc. (NASDAQ:PRPO) issued its earnings results on Thursday, November, 10th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter. The biotechnology company had revenue of $2.22 million for the quarter. Precipio had a negative net margin of 128.09% and a negative trailing twelve-month return on equity of 56.55%.
When did Precipio's stock split?: Precipio shares reverse split on the morning of Tuesday, June 6th 2017. The 1-30 reverse split was announced on Thursday, May 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What guidance has Precipio issued on next quarter's earnings?: Precipio issued an update on its first quarter 2023 earnings guidance on Wednesday, January, 11th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $7.34 million-$7.34 million, compared to the consensus revenue estimate of $5.86 million.
What other stocks do shareholders of Precipio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Precipio investors own include Biocept (BIOC), Heat Biologics (HTBX), Portola Pharmaceuticals (PTLA), iBio (IBIO), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), VBI Vaccines (VBIV), Co-Diagnostics (CODX), Inpixon (INPX) and Jaguar Health (JAGX).
What is Precipio's stock symbol?: Precipio trades on the NASDAQ under the ticker symbol "PRPO."
How do I buy shares of Precipio?: Shares of PRPO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Precipio's stock price today?: One share of PRPO stock can currently be purchased for approximately $0.89.
How much money does Precipio make?: Precipio (NASDAQ:PRPO) has a market capitalization of $20.31 million and generates $8.85 million in revenue each year. The biotechnology company earns $-8,530,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis.
How can I contact Precipio?: Precipio's mailing address is 4 Science Park, New Haven CT, 06511. The official website for the company is www.precipiodx.com. The biotechnology company can be reached via phone at (203) 787-7888, via email at investors@precipiodx.com, or via fax at 402-452-5401.

This page (NASDAQ:PRPO) was last updated on 1/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Precipio - PRPO Stock Forecast, Price & News

Precipio MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About Precipio (NASDAQ:PRPO) Stock

PRPO Stock News Headlines

PRPO Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

PRPO Stock - Frequently Asked Questions

Overall MarketRank^™